NewAmsterdam Pharma Company N.V. Ordinary Shares

Net selling: insiders sold $4.7M and bought $227K of NAMS stock on the open market in the 90 days to Oct 24, 2026, according to SEC Form 4 filings. $4.6M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Kastelein, Johannes Jacob Pieter (Chief Scientific Officer), who sold $4.6M. The latest filing was on Oct 2, 2026.

None. No member of Congress disclosed a NAMS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

This summary uses filings available on Oct 24, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.